Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P0DML2

UPID:
CSH1_HUMAN

ALTERNATIVE NAMES:
Lactogen; Placental lactogen

ALTERNATIVE UPACC:
P0DML2; P01243; Q0VDB1; Q14407

BACKGROUND:
The protein Chorionic somatomammotropin hormone 1, with alternative names Lactogen and Placental lactogen, is crucial for pregnancy-related physiological processes. It stimulates lactation, supports fetal growth, and regulates metabolism, acting through PRLR activation via zinc-induced dimerization, distinct from GHR interactions.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Chorionic somatomammotropin hormone 1 offers a promising avenue for developing novel therapeutic approaches. Its critical involvement in pregnancy underscores its potential impact on improving outcomes in maternal and fetal health.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.